Opioid Detoxification and Naltrexone Induction Strategies: Recommendations for Clinical Practice
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Opioid dependence is a significant public health problem associated with high risk for relapse if treatment is not ongoing. While maintenance on opioid agonists (i.e., methadone, buprenorphine) often produces favorable outcomes, detoxification followed by treatment with the μ-opioid receptor antagonist naltrexone may offer a potentially useful alternative to agonist maintenance for some patients. METHOD: Treatment approaches for making this transition are described here based on a literature review and solicitation of opinions from several expert clinicians and scientists regarding patient selection, level of care, and detoxification strategies. CONCLUSION: Among the current detoxification regimens, the available clinical and scientific data suggest that the best approach may be using an initial 2-4 mg dose of buprenorphine combined with clonidine, other ancillary medications, and progressively increasing doses of oral naltrexone over 3-5 days up to the target dose of naltrexone. However, more research is needed to empirically validate the best approach for making this transition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Release from prison–a high risk of death for former inmates
Binswanger, I. A., Stern, M. F., Deyo, R. A., Heagerty, P. J., Cheadle, A., Elmore, J. G., & Koepsell, T. D. (2007) · New England Journal of Medicine · doi:10.1056/nejmsa064115 · Cited by 1,684
Management of Drug and Alcohol Withdrawal
Kosten, T. R., & O'Connor, P. G. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020617 · Cited by 563
Self-citationKrupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60358-9 · Cited by 555
Self-citationBuprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub3 · Cited by 501
Historical review: molecular and cellular mechanisms of opiate and cocaine addiction
Nestler, E. J. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.02.005 · Cited by 425 · cited 1×
“Abrupt cessation of opioids in persons who are physiologically dependent results in an overactivity of the noradrenergic system (locus ceruleus, periaqueductal gray region) and possible decreased dopamine activity in the ventral tegmental area resulting in symptoms that are almost a mirror opposite of agonist effects…”
BackgroundA randomized clinical trial of methadone maintenance for prisoners: Results at 12 months postrelease
Kinlock, T. W., Gordon, M. S., Schwartz, R. P., Fitzgerald, T. T., & O'Grady, K. E. (2009) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2009.03.002 · Cited by 235
Hulse, G. K., Morris, N., Arnold-Reed, D., & Tait, R. J. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.130 · Cited by 135 · cited 1×
“Over the past decade, the problem of poor adherence to oral naltrexone has begun to be addressed through the development of both injectable (20) and surgically implantable (21,22) sustained-release formulations that circumvent the need for daily oral doses.”
BackgroundNaltrexone and buprenorphine combination in the treatment of opioid dependence
Gerra, G., Fantoma, A., & Zaimovic, A. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106060835 · Cited by 106 · cited 1×
“One study suggested that adding a daily dose of buprenorphine once patients achieve a therapeutic dose of naltrexone might suppress cocaine use via its antagonist effects on the κ-opioid receptor and agonist effects at the nociceptin-opioid receptor (96).”
BackgroundKrupitsky, E. M., Zvartau, E. E., Masalov, D. V., Tsoy, M. V., Burakov, A. M., Egorova, V. Y., Didenko, T. Y., Romanova, T. N., Ivanova, E. B., Bespalov, A. Y., et al. (2006) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2006.05.005 · Cited by 93
Self-citationDunn, K. E., Sigmon, S. C., Strain, E. C., Heil, S. H., & Higgins, S. T. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.05.033 · Cited by 65
Self-citation
Cited by
Medication-Assisted Treatment of Opioid Use Disorder: Review of the Evidence and Future Directions
Connery, H. S. (2015) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000075 · Cited by 576
Treatment of opioid-use disorders
Schuckit, M. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1604339 · Cited by 540
The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update
(2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000633 · Cited by 412
Tanum, L., Solli, K. K., Latif, Z.-E.-H., Benth, J. Š., Opheim, A., Sharma-Haase, K., Krajci, P., & Kunøe, N. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3206 · Cited by 253
Kosten, T. R., & Baxter, L. E. (2019) · The American Journal on Addictions · doi:10.1111/ajad.12862 · Cited by 235
“Few patients are able to achieve this goal without medical assistance and a variety of opioid discontinuation protocols have been employed using short courses of buprenorphine in combination with non-opioid adjunctive medications and sometimes with increasing (but low) doses of naltrexone.(16,38) For patients with low…”
BackgroundSelf-citation
Metadata
- Authors
- Sigmon, S. C., Bisaga, A., Nunes, E. V., O'Connor, P. G., Kosten, T., & Woody, G.
- Venue
- The American Journal of Drug and Alcohol Abuse
- Publisher
- Informa UK Limited
- Published
- 2012-03-12
- Volume
- 38
- Issue
- 3
- Pages
- 187-199
- ISSN
- 0095-2990 (ISSN-L)
- 1097-9891
- OpenAlex
- W2002469502
- Cited by
- 127
- References
- 10
- FWCI
- 5.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.